source
- Sanofi halts development of Nurix-partnered STAT6 degrader, triggering sharp drop in Nurix stockSanofi announced it is ending work on SAR448272, an experimental oral drug that was intended to degrade the STAT6 protein, which is linked to inflammatory diseases. The biotech firm Nurix, which l…
- Analysts predict biopharma gains as Democrats take Congress controlAnalysts say the biopharma sector is set to benefit from the recent shift in U.S. Congress, with Democrats now holding majorities in both the House and Senate. They note that drug‑pricing debates…